Biocon Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon Limited's Board approved audited financial results for Q4 and FY ended March 31, 2026 (actual numbers not included in filing). The Board recommended a final dividend of Rs. 0.50 per equity share (10%) for FY2026, payable by August 31, 2026, with record date July 3, 2026. Statutory auditors will change from B S R & Co. LLP to S. R. Batliboi & Associates LLP for a 5-year term from the 48th AGM. Six new directors are being appointed including former Viatris/Mylan President Rajiv Malik and biotech veteran Daniel Bradbury. The Company approved acquiring the remaining ~2% equity stake in subsidiary Biocon Biologics Limited (BBL) through issuance of 87.92 million Biocon shares worth Rs. 330.73 crore, and conversion of OCDs and CCDs of BBL into equity shares, taking its holding in BBL to ~99.99%. The Board also approved a Long-Term Incentive Plan (Biocon Unity LTIP 2026).
The auditor change and multiple director appointments signal governance evolution ahead of BBL full integration. The share-swap acquisition at Rs. 376.16 per share will dilute existing shareholders by ~87.92 million shares but consolidates the biosimilars business under one roof. Dividend continuity reflects financial stability.